Drug Trial Radar · NCT06941415
Bumetanide vs. Furosemide in Cirrhosis
Last checked: Nov 20, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Jun 3, 2026
Primary completion
Mar 1, 2029
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- Stacy JohnsonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with cirrhosis are frequently hospitalized due to an acute decompensation of their liver disease including bleeding, jaundice, encephalopathy, and volume overload. Volume overload is associated with increased mortality from acute hypoxic respiratory failure, hemorrhage from esophageal varices, and spontaneous bacterial peritonitis. Clinical practice guidelines describe sodium restriction and diuretics as first-line treatment, combined with regular body weight monitoring to assess response. In patients with suboptimal response to furosemide, alternative loop diuretics like torsemide or bumetanide may improve natriuresis. Bumetanide has a theoretic advantage over furosemide due to its more rapid and complete intestinal absorption, combined with a prolonged half-life in patients with hepatic dysfunction. In this pragmatic study, the aim is to compare the efficacy of diuresis with bumetanide versus furosemide among hospitalized patients with cirrhosis.
Conditions
- Cirrhosis
Interventions
BumetanideDrug
Standard of care treatment with bumetanide (intravenous or oral administration) per treating clinician's orders
FurosemideDrug
Standard of care treatment with furosemide (intravenous or oral administration) per treating clinician's orders
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in weightTime frame: 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Utah Hospital
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.